Nifty
:
25461.00
Sensex
:
83432.89
55.70 (0.22%)
193.42 (0.23%)
Nifty
Sensex
:
:
25461.00
83432.89
55.70 (0.22%)
193.42 (0.23%)

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
59/99

BSE: 533573 | NSE: APLLTD

NSE BSE
1000.70
04-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1010.5
  •  1010.5
  •  993
  •  1007.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  108238
  •  108132472.5
  •  1303.9
  •  725.2

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 19,665.16
  • 33.71
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,770.64
  • 1.10%
  • 3.79

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.67%
  • 0.16%
  • 7.07%
  • FII
  • DII
  • Others
  • 3.94%
  • 16.08%
  • 3.08%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.74
  • 4.35
  • 5.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.02
  • -7.49
  • 7.21

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -2.08
  • -12.15
  • 19.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.98
  • 28.42
  • 33.16

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.75
  • 3.43
  • 3.33

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.82
  • 16.78
  • 18.94

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
31.33
29.68
36.67
47.2
P/E Ratio
31.94
33.72
27.29
21.20
Revenue
6229
6672
7406
8213
EBITDA
933
1008
1232
1498
Net Income
616
583
721
928
ROA
9.8
8.2
11.1
13.3
P/B Ratio
4.01
3.79
3.45
3.08
ROE
13.4
11.66
13.19
15.27
FCFF
430
-548
595
589
FCFF Yield
2.09
-2.66
2.89
2.86
Net Debt
387
1167
491
67
BVPS
249.74
264.1
289.96
324.74

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
1,769.64
1,516.97
16.66%
1,692.75
1,630.57
3.81%
1,647.98
1,594.93
3.33%
1,561.73
1,486.15
5.09%
Expenses
1,497.71
1,256.92
19.16%
1,432.52
1,364.21
5.01%
1,408.71
1,386.69
1.59%
1,324.90
1,287.45
2.91%
EBITDA
271.93
260.05
4.57%
260.23
266.36
-2.30%
239.27
208.24
14.90%
236.83
198.70
19.19%
EBIDTM
15.37%
17.14%
15.37%
16.34%
14.52%
13.06%
15.16%
13.37%
Other Income
14.19
3.60
294.17%
9.50
2.89
228.72%
16.74
10.15
64.93%
2.10
11.66
-81.99%
Interest
24.52
10.94
124.13%
22.26
15.17
46.74%
18.81
15.69
19.89%
13.18
14.39
-8.41%
Depreciation
68.99
69.48
-0.71%
70.04
69.45
0.85%
70.51
67.56
4.37%
69.04
66.18
4.32%
PBT
192.61
183.23
5.12%
177.43
184.63
-3.90%
179.56
135.14
32.87%
156.71
129.79
20.74%
Tax
35.32
4.63
662.85%
40.09
4.13
870.70%
27.28
-1.93
-
22.49
9.16
145.52%
PAT
157.29
178.60
-11.93%
137.34
180.50
-23.91%
152.28
137.07
11.10%
134.22
120.63
11.27%
PATM
8.89%
11.77%
8.11%
11.07%
9.24%
8.59%
8.59%
8.12%
EPS
7.98
9.07
-12.02%
7.04
9.18
-23.31%
7.81
6.95
12.37%
6.85
6.14
11.56%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
-
6,672.08
6,228.63
5,652.62
5,305.78
5,393.14
4,605.76
3,934.69
3,130.81
3,134.61
3,165.99
Net Sales Growth
-
7.12%
10.19%
6.54%
-1.62%
17.10%
17.06%
25.68%
-0.12%
-0.99%
 
Cost Of Goods Sold
-
1,793.36
1,715.08
1,708.82
1,446.43
1,257.35
1,039.38
992.71
886.19
887.57
823.95
Gross Profit
-
4,878.72
4,513.55
3,943.80
3,859.35
4,135.79
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
GP Margin
-
73.12%
72.46%
69.77%
72.74%
76.69%
77.43%
74.77%
71.69%
71.68%
73.97%
Total Expenditure
-
5,669.16
5,296.00
4,944.56
4,431.64
3,913.05
3,391.69
3,078.87
2,515.55
2,519.90
2,160.88
Power & Fuel Cost
-
179.69
173.37
151.54
120.84
118.72
102.40
88.86
70.35
64.20
58.89
% Of Sales
-
2.69%
2.78%
2.68%
2.28%
2.20%
2.22%
2.26%
2.25%
2.05%
1.86%
Employee Cost
-
1,562.34
1,446.29
1,169.13
1,133.00
1,051.17
906.44
746.69
622.81
558.83
472.85
% Of Sales
-
23.42%
23.22%
20.68%
21.35%
19.49%
19.68%
18.98%
19.89%
17.83%
14.94%
Manufacturing Exp.
-
440.63
387.71
409.37
379.15
372.18
368.41
269.25
244.53
289.79
271.51
% Of Sales
-
6.60%
6.22%
7.24%
7.15%
6.90%
8.00%
6.84%
7.81%
9.24%
8.58%
General & Admin Exp.
-
576.40
525.84
492.64
413.90
391.24
339.82
340.56
283.43
299.79
233.28
% Of Sales
-
8.64%
8.44%
8.72%
7.80%
7.25%
7.38%
8.66%
9.05%
9.56%
7.37%
Selling & Distn. Exp.
-
1,064.86
996.88
952.30
890.38
687.41
531.19
590.28
380.21
393.14
274.14
% Of Sales
-
15.96%
16.00%
16.85%
16.78%
12.75%
11.53%
15.00%
12.14%
12.54%
8.66%
Miscellaneous Exp.
-
51.88
50.83
60.76
47.94
34.98
104.05
50.52
28.03
26.58
274.14
% Of Sales
-
0.78%
0.82%
1.07%
0.90%
0.65%
2.26%
1.28%
0.90%
0.85%
0.83%
EBITDA
-
1,002.92
932.63
708.06
874.14
1,480.09
1,214.07
855.82
615.26
614.71
1,005.11
EBITDA Margin
-
15.03%
14.97%
12.53%
16.48%
27.44%
26.36%
21.75%
19.65%
19.61%
31.75%
Other Income
-
47.86
29.04
3.04
50.49
87.48
13.88
27.14
34.87
2.58
8.83
Interest
-
78.77
56.19
50.17
17.73
16.02
27.16
18.41
3.40
5.23
5.43
Depreciation
-
278.57
272.67
275.43
286.78
183.47
157.32
115.23
105.46
82.97
72.21
PBT
-
693.44
632.81
385.50
620.12
1,368.08
1,043.47
749.32
541.27
529.09
936.30
Tax
-
125.17
16.01
12.60
104.46
253.32
199.18
156.75
120.36
122.19
216.12
Tax Rate
-
17.72%
2.53%
3.27%
16.85%
18.52%
19.92%
20.92%
22.24%
23.09%
23.08%
PAT
-
583.42
615.82
341.99
520.94
1,114.76
828.76
593.65
420.72
406.99
720.18
PAT before Minority Interest
-
582.01
615.82
341.99
520.94
1,114.76
800.64
592.57
420.91
406.90
720.18
Minority Interest
-
1.41
0.00
0.00
0.00
0.00
28.12
1.08
-0.19
0.09
0.00
PAT Margin
-
8.74%
9.89%
6.05%
9.82%
20.67%
17.99%
15.09%
13.44%
12.98%
22.75%
PAT Growth
-
-5.26%
80.07%
-34.35%
-53.27%
34.51%
39.60%
41.10%
3.37%
-43.49%
 
EPS
-
29.68
31.32
17.40
26.50
56.70
42.15
30.20
21.40
20.70
36.63

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
5,190.94
4,818.20
4,370.47
5,237.54
5,066.98
3,219.42
2,718.83
2,220.14
1,902.33
1,597.36
Share Capital
39.31
39.31
39.31
39.31
39.31
37.70
37.70
37.70
37.70
37.70
Total Reserves
5,151.63
4,778.89
4,331.16
5,198.23
5,027.67
3,181.72
2,681.13
2,182.44
1,864.63
1,559.66
Non-Current Liabilities
5.05
2.75
52.42
162.07
361.16
1,046.98
570.06
576.20
94.15
84.02
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
199.89
886.99
499.30
500.00
0.00
0.00
Long Term Provisions
124.31
109.51
106.20
95.82
85.52
74.51
52.03
40.76
57.22
28.23
Current Liabilities
2,514.27
1,520.28
1,640.80
1,830.59
1,533.26
1,751.61
1,663.65
1,267.18
813.96
944.19
Trade Payables
879.89
735.64
679.81
706.39
668.78
625.93
644.34
759.32
500.73
565.65
Other Current Liabilities
232.10
223.66
251.19
516.51
557.92
226.98
380.19
142.89
81.28
51.80
Short Term Borrowings
1,195.57
430.45
635.87
430.00
0.02
860.50
429.13
207.78
88.51
113.71
Short Term Provisions
206.71
130.53
73.93
177.69
306.54
38.20
209.99
157.19
143.44
213.03
Total Liabilities
7,708.84
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
Net Block
2,523.53
2,546.71
2,398.45
1,797.85
1,788.42
1,551.84
1,158.45
993.38
799.40
708.09
Gross Block
4,117.32
3,875.21
3,467.50
2,840.33
2,545.39
2,132.41
1,522.57
1,242.47
950.09
1,093.63
Accumulated Depreciation
1,593.79
1,328.50
1,069.05
1,042.48
756.97
580.57
364.12
249.09
150.69
385.54
Non Current Assets
3,519.12
3,197.39
3,149.80
4,255.37
4,056.96
3,526.30
2,820.02
2,116.31
1,316.80
917.30
Capital Work in Progress
837.23
524.36
601.28
2,304.24
2,182.53
1,846.18
1,551.23
1,010.15
396.28
92.52
Non Current Investment
127.21
93.02
96.33
118.40
49.31
17.62
48.76
41.64
49.88
53.43
Long Term Loans & Adv.
31.15
33.30
53.74
34.88
36.70
110.66
61.58
71.14
71.24
29.96
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
33.30
Current Assets
4,189.72
3,143.84
2,913.89
2,974.83
2,904.44
2,462.75
2,131.73
1,947.52
1,493.75
1,708.27
Current Investments
0.00
0.00
0.00
0.00
186.97
0.00
0.00
0.00
0.00
0.00
Inventories
2,288.14
1,643.54
1,475.27
1,609.70
1,486.15
1,187.54
967.27
733.93
632.75
569.79
Sundry Debtors
1,399.79
1,024.84
1,046.41
807.13
348.60
864.75
488.92
526.34
338.82
350.48
Cash & Bank
90.09
126.57
82.27
69.43
105.84
80.75
205.62
89.92
159.60
450.83
Other Current Assets
411.70
59.86
55.32
51.65
776.88
329.71
469.92
597.33
362.58
337.17
Short Term Loans & Adv.
342.52
289.03
254.62
436.92
698.21
301.61
451.71
569.84
355.02
330.08
Net Current Assets
1,675.45
1,623.56
1,273.09
1,144.24
1,371.18
711.14
468.08
680.34
679.79
764.08
Total Assets
7,708.84
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
87.96
803.20
723.94
552.35
1,463.38
449.15
811.97
312.42
328.55
947.65
PBT
707.18
631.83
354.59
625.39
1,368.08
999.82
749.32
541.27
529.09
936.31
Adjustment
373.53
286.87
487.61
417.75
102.42
278.28
117.57
87.12
83.06
69.45
Changes in Working Capital
-921.36
-95.65
-57.56
-367.36
238.30
-592.84
111.56
-180.85
-165.64
138.90
Cash after chg. in Working capital
159.35
823.05
784.64
675.78
1,708.80
685.26
978.45
447.54
446.51
1,144.66
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-71.39
-19.85
-60.70
-123.43
-245.42
-236.11
-166.48
-135.12
-117.96
-197.01
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-568.41
-320.61
-447.59
-371.97
-838.80
-731.63
-755.60
-884.38
-485.91
-306.80
Net Fixed Assets
-554.36
-340.93
994.77
-402.51
-1,303.18
-789.71
-638.70
-606.86
-121.60
-288.80
Net Investments
-32.88
2.59
-9.91
123.73
490.16
-326.86
-207.50
-195.85
-65.58
-4.13
Others
18.83
17.73
-1,432.45
-93.19
-25.78
384.94
90.60
-81.67
-298.73
-13.87
Cash from Financing Activity
443.72
-437.86
-261.96
-217.35
-597.42
154.85
59.03
502.63
-128.88
-224.30
Net Cash Inflow / Outflow
-36.73
44.73
14.39
-36.97
27.16
-127.63
115.40
-69.33
-286.24
416.55
Opening Cash & Equivalents
120.21
75.48
61.09
98.06
71.83
199.06
83.74
153.07
439.32
22.77
Closing Cash & Equivalent
83.48
120.21
75.48
61.09
98.06
71.84
199.07
83.74
153.08
439.32

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
264.10
245.14
222.36
266.47
257.80
170.79
144.24
117.78
100.92
84.74
ROA
8.28%
9.93%
5.15%
7.34%
17.22%
14.64%
13.15%
12.25%
14.97%
33.76%
ROE
11.63%
13.40%
7.12%
10.11%
26.91%
26.97%
24.00%
20.42%
23.25%
58.03%
ROCE
13.51%
13.42%
7.44%
11.25%
26.28%
23.30%
22.66%
22.15%
28.87%
65.87%
Fixed Asset Turnover
1.67
1.70
1.79
1.97
2.31
2.52
2.85
2.86
3.07
3.24
Receivable days
66.32
60.69
59.84
39.75
41.06
53.64
47.09
50.43
40.13
41.02
Inventory Days
107.54
91.38
99.60
106.49
90.48
85.38
78.91
79.67
70.01
54.91
Payable days
164.40
150.62
148.04
173.51
187.92
69.87
88.23
98.47
84.03
80.04
Cash Conversion Cycle
9.46
1.45
11.40
-27.27
-56.39
69.15
37.76
31.63
26.12
15.89
Total Debt/Equity
0.23
0.09
0.15
0.12
0.10
0.54
0.42
0.32
0.05
0.07
Interest Cover
9.98
12.24
8.07
36.27
86.40
37.81
41.70
160.20
102.16
173.43

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Alembic Pharmaceuticals’ arm to acquire Utility Therapeutics
    3rd Jul 2025, 09:39 AM

    The objective behind the acquisition is to market the USFDA approved product and underdevelopment product owned by the Utility in USA

    Read More
  • Alembic Pharmaceuticals gets final nod for Doxorubicin Hydrochloride Liposome Injection
    30th Jun 2025, 10:11 AM

    The company has a cumulative total of 224 ANDA approvals (201 final approvals and 23 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets EIR from USFDA for API-III facility at Karakhadi
    18th Jun 2025, 14:51 PM

    Earlier, the company had successfully completed the USFDA inspection for its API-III Facility located at Karakhadi

    Read More
  • USFDA concludes inspection at Alembic Pharmaceuticals’ Gujarat API-I & II facility
    2nd Jun 2025, 09:17 AM

    The USFDA issued a Form 483 with four observations

    Read More
  • Alembic Pharmaceuticals receives USFDA's final approval for Bosutinib Tablets
    31st May 2025, 12:30 PM

    The company has a cumulative total of 223 ANDA approvals (200 final approvals and 23 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s nod for Amlodipine and Atorvastatin Tablets
    23rd May 2025, 15:30 PM

    The company has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final nod for Rivaroxaban Tablets USP
    15th May 2025, 14:29 PM

    Rivaroxaban Tablets USP, 2.5 mg, has an estimated market size of $445 million for twelve months ending March 2025

    Read More
  • Alembic Pharmaceuticals receives USFDA’s final approval for Ticagrelor Tablets
    2nd May 2025, 17:34 PM

    The company has a cumulative total of 222 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals commissions new manufacturing facility in Madhya Pradesh
    26th Apr 2025, 15:20 PM

    The investment made for said manufacturing facility is approximately Rs 205 crore

    Read More
  • Alembic Pharmaceuticals gets USFDA’s nod for Carbamazepine Tablets
    17th Apr 2025, 14:20 PM

    Alembic has a cumulative total of 222 ANDA approvals (196 final approvals and 26 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals receives USFDA’s final approval for Pantoprazole Sodium Injection
    1st Apr 2025, 16:30 PM

    Alembic has a cumulative total of 221 ANDA approvals from USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.